With the 5th approval on CAR-T therapy (Abecma) by FDA in early 2021, ex vivo engineered T cell therapy was proved as a mainstay in cancer treatment.
05-19-2021 Dr. Lumeng Ye, Senior Scientist R&D department
With the 4th approval on CAR-T therapy (Breyanzi) by FDA in early 2021, ex vivo engineered T cell therapy was proved as a mainstay in cancer treatment.
04-28-2021 Lumeng Ye, Ph.D. Senior Scientist @Genscript, USA
Genome Engineering allows the easy manipulation of genomes down to the nucleotide level.
11-03-2020 Shondra M. Pruett-Miller, Ph.D. Director
Design high specificity CRISPR/Cas9 gRNAs: principles and tools
09-09-2020 Design high specificity CRISPR/Cas9 gRNAs: principles and tools
The CRISPR/Cas9 system has made targeted gene editing easily accessible for research and therapeutic purposes.
05-07-2020 James Chon, Ph.D.
Genome editing has always been a challenging area as a means to provide more efficient ways to create a meaningful change in the genome.
05-06-2020 Dr. Edward Wong, Field Application Scientist, GenScript
